How South Korea Can Win In The Global Clinical Trial Arena
South Korea remains an attractive location for clinical trials, but as seen in recent sharp increases in activity in rival Asian countries, a rapidly changing regulatory and market environment are posing challenges. Syneos Health's CSO talks to Scrip about the pros and cons of Korea as a clinical trial site versus other Asia Pacific locations, and how the country can attract further studies into the country.
You may also be interested in...
South Korea’s Qurient achieves proof of concept in a Phase II study with its first-in-class antibiotic telacebec for tuberculosis and aims to file a US NDA for the orphan drug.
Although the pandemic could slightly delay CrystalGenomics’ business and R&D plans, the South Korean biotech is still hopeful this year will bring long-awaited progress for anticancer candidate ivaltinostat as well as discovery of its potential as a treatment for the new coronavirus.
A trade institute's recent report emphasizes that government support is still needed although South Korean CRO industry has grown sharply in recent years and suggests ways to improve global competitiveness.